NDAINJECTIONINJECTABLE
Approved
Jun 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TECHNESCAN MAG3 (technescan tc 99m mertiatide) by Curium Pharma is clinical pharmacology following intravenous injection of technetium tc 99m mertiatide, the appearance, concentration, and excretion of the tracer in the kidney can be monitored to assess renal function. First approved in 1990.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECHNESCAN MAG3 is a technetium Tc 99m-labeled radiopharmaceutical diagnostic agent administered by intravenous injection to assess renal function and monitor kidney appearance, concentration, and excretion. The tracer undergoes rapid renal clearance via both glomerular filtration and active tubular secretion, enabling clinicians to detect functional impairment in patients with suspected renal disease.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand teams should anticipate declining market share and resource consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Following intravenous injection of technetium Tc 99m mertiatide, the appearance, concentration, and excretion of the tracer in the kidney can be monitored to assess renal function. Although technetium Tc 99m mertiatide is highly plasma protein bound following intravenous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on TECHNESCAN MAG3 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.